Holen Sie sich die Stockscreener-App
24.40
4.46%
-1.14
Handel nachbörslich:
24.51
0.11
+0.45%
Schlusskurs vom Vortag:
$25.54
Offen:
$27.2
24-Stunden-Volumen:
31.50M
Relative Volume:
1.69
Marktkapitalisierung:
$5.55B
Einnahmen:
$1.78B
Nettoeinkommen (Verlust:
$164.40M
KGV:
35.36
EPS:
0.69
Netto-Cashflow:
$236.51M
1W Leistung:
-14.89%
1M Leistung:
-26.97%
6M Leistung:
-61.48%
1J Leistung:
-41.70%
1-Tages-Spanne:
$23.99
$27.20
1-Wochen-Bereich:
$23.99
$30.70
52-Wochen-Spanne:
$23.97
$72.98
Hims Hers Health Inc Stock (HIMS) Company Profile
Firmenname
Hims Hers Health Inc
Sektor
Telefon
415-851-0195
Adresse
2269 CHESTNUT ST, SAN FRANCISCO
Vergleichen Sie HIMS mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
HIMS
Hims Hers Health Inc
|
24.40 | 5.81B | 1.78B | 164.40M | 236.51M | 0.69 |
|
TAK
Takeda Pharmaceutical Co Adr
|
17.74 | 55.06B | 29.85B | 776.90M | 4.35B | 0.2408 |
|
ZTS
Zoetis Inc
|
126.70 | 53.95B | 9.40B | 2.65B | 2.24B | 5.935 |
|
HLN
Haleon Plc Adr
|
10.78 | 46.71B | 14.26B | 1.98B | 2.47B | 0.4327 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
34.96 | 41.68B | 17.41B | 1.43B | 774.28M | 1.219 |
|
UTHR
United Therapeutics Corp
|
482.59 | 20.59B | 3.13B | 1.27B | 1.12B | 26.39 |
Hims Hers Health Inc Stock (HIMS) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-01-12 | Eingeleitet | Evercore ISI | In-line |
| 2025-12-09 | Eingeleitet | Barclays | Overweight |
| 2025-10-21 | Eingeleitet | KeyBanc Capital Markets | Sector Weight |
| 2025-06-23 | Herabstufung | Needham | Buy → Hold |
| 2025-06-04 | Bestätigt | Needham | Buy |
| 2025-04-29 | Herabstufung | TD Cowen | Buy → Hold |
| 2025-02-18 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2025-01-10 | Herabstufung | Citigroup | Neutral → Sell |
| 2025-01-07 | Eingeleitet | BTIG Research | Buy |
| 2024-12-17 | Eingeleitet | Morgan Stanley | Overweight |
| 2024-11-14 | Herabstufung | BofA Securities | Buy → Underperform |
| 2024-08-22 | Eingeleitet | Needham | Buy |
| 2024-08-09 | Herabstufung | Imperial Capital | Outperform → In-line |
| 2024-05-22 | Herabstufung | Citigroup | Buy → Neutral |
| 2024-04-16 | Herabstufung | Jefferies | Buy → Hold |
| 2024-04-10 | Eingeleitet | Canaccord Genuity | Buy |
| 2024-02-28 | Hochstufung | Imperial Capital | In-line → Outperform |
| 2024-02-26 | Eingeleitet | Leerink Partners | Market Perform |
| 2023-12-07 | Eingeleitet | Imperial Capital | In-line |
| 2023-07-28 | Eingeleitet | TD Cowen | Outperform |
| 2023-04-11 | Eingeleitet | Robert W. Baird | Neutral |
| 2023-02-09 | Hochstufung | Jefferies | Hold → Buy |
| 2022-11-08 | Hochstufung | BofA Securities | Neutral → Buy |
| 2022-11-08 | Hochstufung | SVB Leerink | Mkt Perform → Outperform |
| 2022-10-17 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2022-09-07 | Eingeleitet | Truist | Hold |
| 2022-07-15 | Eingeleitet | SVB Leerink | Underperform |
| 2022-04-14 | Eingeleitet | Guggenheim | Buy |
| 2022-04-01 | Fortgesetzt | Credit Suisse | Outperform |
| 2022-03-10 | Eingeleitet | Deutsche Bank | Hold |
| 2021-12-02 | Eingeleitet | Jefferies | Hold |
| 2021-11-11 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2021-07-06 | Eingeleitet | BofA Securities | Neutral |
| 2021-05-20 | Hochstufung | Credit Suisse | Neutral → Outperform |
| 2021-04-21 | Eingeleitet | Truist | Hold |
| 2021-03-09 | Eingeleitet | Credit Suisse | Neutral |
| 2021-03-02 | Hochstufung | Citigroup | Neutral → Buy |
| 2021-02-17 | Eingeleitet | Citigroup | Neutral |
| 2021-02-12 | Eingeleitet | Piper Sandler | Neutral |
| 2021-02-08 | Eingeleitet | Tigress Financial | Buy |
Alle ansehen
Hims Hers Health Inc Aktie (HIMS) Neueste Nachrichten
Hims & Hers launches multi-cancer blood test screening for 50+ cancers - Investing.com India
HUGE News: Hims & Hers Adds Cancer Testing to Labs Offering - The Globe and Mail
HUGE News: Hims & Hers Adds Cancer Testing to Labs Offering - The Motley Fool
Hims & Hers Shares In The Spotlight After Launching Multi-Cancer Test - Benzinga
Hims & Hers Offers Multi-Cancer Blood Screening Through New Partnership - marketscreener.com
HIMS Stock Garners Retail Buzz After Launching New Multi-Cancer Detection Test - Stocktwits
Hims & Hers (HIMS) Launches Discounted Multi-Cancer Test - GuruFocus
Hims & Hers launches GRAIL cancer screening test (HIMS:NYSE) - Seeking Alpha
Hims & Hers stock rises after launching multi-cancer detection test By Investing.com - Investing.com Canada
Hims & Hers stock rises after launching multi-cancer detection test - Investing.com India
Hims & Hers Launches Multi-Cancer Early Detection Testing, Connecting Customers to Cutting-Edge Proactive Care - itemonline.com
Hims adds cancer detection test to Labs product - Sherwood News
The healthcare companies advertising in Super Bowl LX - Modern Healthcare News
Is HIMS Stock Undervalued in 2026 After a 32% Decline Last Year? - TIKR.com
Peak Retirement Planning Inc. Invests $2.84 Million in Hims & Hers Health, Inc. $HIMS - MarketBeat
119,279 Shares in Hims & Hers Health, Inc. $HIMS Purchased by Pathway Capital Management LP - MarketBeat
Hims & Hers Health (HIMS) Stock Price, Quote, News & History - Benzinga
(HIMS) Movement Within Algorithmic Entry Frameworks - Stock Traders Daily
Hims & Hers Health, Inc. (HIMS) Stock Dips While Market Gains: Key Facts - Yahoo Finance
Hims & Hers Health to Release 2025 Financial Results on February 23, 2026 - geneonline.com
Hims & Hers to Announce Fourth Quarter and Full Year 2025 Financial Results on February 23, 2026 - investors.hims.com
Key facts: BTIG Cuts Hims & Hers Price Target to $60; ROIC Improves - TradingView
Hims Super Bowl Push Links Healthcare Inequality Message With Valuation Gap - Yahoo Finance
BTIG Research Cuts Hims & Hers Health (NYSE:HIMS) Price Target to $60.00 - MarketBeat
BTIG Lowers HIMS Price Target to $60, Maintains Buy Rating | HIMS Stock News - GuruFocus
Hims & Hers Health (HIMS): Buy, Sell, or Hold Post Q3 Earnings? - Finviz
Hims and Hers Super Bowl ad highlights ‘uncomfortable truth’ about elite healthcare for the rich and ‘broken’ system for the rest - Yahoo Finance
Hims & Hers Bets Big on Provocative Super Bowl Ad Strategy - AD HOC NEWS
Promising Healthcare Stocks To ConsiderJanuary 3rd - MarketBeat
OMCL or HIMS: Which Is the Better Value Stock Right Now? - Yahoo Finance
Hims & Hers returns with another Super Bowl ad one year after controversy - Medical Marketing and Media
Hims & Hers: A Platform Strategy Pivot Driving Long-Term Value (NYSE:HIMS) - Seeking Alpha
Hims’ Super Bowl Ad Cost $16 Million and Nearly a Year’s Worth of Effort - inc.com
Assessing Hims & Hers Health (HIMS) Valuation As Estimate Cuts And Big Game Ad Campaign Shape Sentiment - simplywall.st
Hims & Hers Wants To ‘Ruffle Some Feathers’ With Provocative Super Bowl Ad - Athletech News
HIMS Stock Sees Surge in Call Option Activity - GuruFocus
Super Bowl updates—see Hims, Novartis, Pepsi and Toyota’s full spots - Ad Age
Hims & Hers Super Bowl Commercial Spotlights Cancer Detection, Glp-1 Microdoses - IMDb
Health care and pharma brands are going all-in on the Super Bowl—behind the growing trend - Ad Age
Hims & Hers Returns to the Big Game with a Message to All Americans: The Era of Health as a Luxury is Over - Rutland Herald
Hims & Hers attacks the rich in its Super Bowl ad — including a Jeff Bezos lookalike - Business Insider
The Health Gap is a Wealth Gap. That Stops next Sunday. - Hims & Hers Newsroom
Hims & Hers Returns To Super Bowl With Ad That Spotlights The Health-Wealth Gap - Forbes
Hims & Hers: It's Time To Get Aggressive (NYSE:HIMS) - Seeking Alpha
Jack Abraham Board Role Links Hims And Hers To Research Frontline - Sahm
Surging Q3 Revenue And Cash Pile Could Be A Game Changer For Hims & Hers Health (HIMS) - Yahoo Finance
Cold Spring Harbor Laboratory Appoints Jack Abraham and Terri Keogh to Board of Trustees - Yahoo Finance Singapore
Hims & Hers Health, Inc. (HIMS) Stock Declines While Market Improves: Some Information for Investors - Yahoo Finance
HIMS Stock Sees Bearish Sentiment Amidst Increased Volatility - GuruFocus
Looking At Hims & Hers Health's Recent Unusual Options Activity - Benzinga
Is Trending Stock Hims & Hers Health, Inc. (HIMS) a Buy Now? - Yahoo Finance
Finanzdaten der Hims Hers Health Inc-Aktie (HIMS)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.38%
0.81%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):